CEPHALOSPORIN DERIVATIVES

Abstract: Cephalosporin derivatives useful as antibiotics have the general formula (I): wherein R₁ is R₂ is -OR₃ wherein R₃ is a hydrogen atom, an alkyl group having 1 to 4 carbon atoms or a pharmaceutically accept­ able cation, -NH-(CH₂) n OH wherein n is 0,1 or 2, -NH CH₂COOR₃ wherein R₃ is as defined above; or -COR₂ together with -CH₂OCOCH₃ form a lactone ring.

Description: DESCRIPTION "CEPHALOSPORIN DERIVATIVES" The present invention relates to cephalosporin compounds, their preparation and pharmaceutical compositions containing them. Cephalosporins are well known as excellent antibiotics due to their selective toxicity to bacteria. However, cephalosporin antibiotics have a serious defect, that is they may disturb the beneficial bacterial colonies ordinarily present in living bodies, particularly the intestinal bacterial colonies, since the cephalosporins may be also antibacterially active against the beneficial bacteria. This defect is very serious when such an antibiotic is orally administered. As a result, microbisme selection et substitute" is caused resulting in colitis and diarrhoea. The present invention is concerned with antibiotics without this defect. In particular, the present invention relates to a compound obtained by chemically modifying a cephalosporin, antibacterial activity being lost by such a chemical modification but recovered when the compound is absorbed into a living body. The cephalosporins of the invention can be formulated into pharmaceutical compositions to provide a medicine exhibiting an antibacterial activity similar to a cephalosporin antibiotic in living body. Compounds of the present invention (hereinafter referred to as the present compound) have the general formula (I): EMI2.1 wherein R1 is EMI2.2 and R2 is -OR3 wherein R3 is a hydrogen atom, an alkyl group having 1 to 4 carbon atoms or a pharmaceutically active, preferably an alkali metal, wherein n is O, 1 or 2; or EMI2.3 wherein R3 is the same meaning as above. The present compound may therefore be in a form other than an alkali metal salt, for example an alkali earth metal salt, aluminum salt or ammonium salt. As a further alternative, a lactone ring may be formed by combining -COR2 and -CH2OCOCH3 groups. The cephalosporins of formula (I), and indeed all cephalosporins described and illustrated by formulae herein, have the usual absolute cephalosporin stereochemistry of 6R:7R. The present compound is derived from a cephalosporin antibiotic by a chemical modification. It is absorbed into a living body without affecting the bacterial colonies ordinarily present in living bodies and shows an antibacterial activity only when entering into blood. Therefore, the present compound is an antibiotic of a new type quite different from the conventional cephalosporin antibiotics. The present compound may be synthesized by the following process. 7-Aminocephalosporanic acid having the general formula (II); EMI3.1 or an alkyl ester or salt thereof is added into an acetone solution of acid chloride of the formula (III); EMI3.2 drop by drop in a mixed solvent of water and acetone in the presence of alkali metal The whole system is brought into reaction for 0.5 to 48 hours at a temperature of -30 to +400C. After the reaction is over, the present compound is collected by the conventional method such as extraction with a solvent, washing with a solvent and recrystallization. The thus-obtained present compound wherein R2 is -OR3 is dissolved in an organic solvent, for example, benzene, tetrahydrofuran, dimethylformamide, chloroform, pyridine, dicyclohexylamine, acetone, triethylamine, chloromethane, dioxane, methanol, ethanol, water, ether and the like. It is preferable to add an activating agent such as carbodiimide, ethyl chloroformate, oxalyl chloride and the like. Then into the thus-prepared solution, an amine compound having the general formula (IV); NH2-R4 (IV) wherein R4 is EMI4.1 wherein n and R3 are the same meanings as above, is added. The whole system is brought into reaction at the temperature of -30 to +500C for 0.5 to 48 hours. After the reaction is over, the present compound is collected by the conventional method such as extraction with a solvent, washing with a solvent, recrystallization and the like. The thus-obtained product is further treated in a mixed solvent of dioxane and 2N-hydrochloric acid solution while shaking to obtain the present compound having a lactone ring. As seen from Examples described below, the present compound has low toxicity and exhibits an antibacterial activity in living body without affecting the intestinal bacterial colonies. The present compound can be useful in the same field as the conventional cephalosporin antibiotics since the present compound is transformed into a cephalosporin antibiotic in a living body. The present compound can be used in a dosage unit form such as a drug or a pharmaceutical composition. The composition may contain 0.01 to 99.5% by weight, generally 0.1 to 90% by weight of the present compound as an active ingredient. The pharmaceutical composition contains a pharmaceutically acceptable carrier, diluent or adjuvant as well as at least one of the present compound. Further, the composition may contain filler, extender, binder, wetting agent, disintegrant, retarder of dissolution, accelerator of reabsorption, adhesive carrier and/or lubricant, for example, starch, mannitol, silicic acid, cellulose derivative, gelatin, alginate, glycerol, agar, calcium carbonate, sodium hydrogen carbonate, paraffin, quartarnary ammonium compound, glycerol monostearate, kaolin, bentonite, talc, potassium stearate, polyethylene glycol and the like. The pharmaceutical composition may be administered orally or rectally or by injection. The dosage form for oral administration may be tablet, capsule, powder, granule, pill, ampoule or the like. The composition may be also in the form of pharmaceutically acceptable emulsion, solution, suspension and the like. A syrup or elixir may contain an inert diluent such as water and paraffin and may be used as a liquid composition suitable for oral administration. These composition may contain an adjuvant such as wetting agent, edulcorant and seasoning agent. A suppository containing the present compound as an active ingredient may contain polyethylene glycol and/or fatty acid or ester thereof. The pharmaceutical composition for injection may be a sterilized aqueous or nonaqueous solution, suspension or emulsion and may contain, for example, propylene glycol, polyethylene glycol, olive oil and the like The present compound may be useful for the same as the conventional cephalosporin antibiotics and effective in treating an infectious disease due to bacteria such as Streptococcus, Pneumococcus, Gonococcus, diphteria bacillus, Staphylococcus, Spirochaeta, Actinomyces, Shigella, E. coli, Myxomycetes, Enterecoccus, Meningococcus and the like. The diseases to be able to be treated with the present compound is exemplified as follows;tonsilitis,pharyngitis,laryn- gitis, wound, burn, postoperative secondary infection, lymphadenitis, septicemia, bacterial endocarditis, pneumonia, pulmonary suppuration, brochitis, scarlet fever, gonorrhea, cystitis, pyothorax, urethritis, bacterial dysentery, meningitis, diphtheria, otitis media, carbuncle, actinomycosis and the like. The dose of the drug or the pharmaceutical composition of the present compound may depend on the degree of the infection and the condition of the patient, and generally the dose of 0.1 to 10 g may be administered to an adult patient per one day, divided into several times. The invention is illustrated in more detail in Examples which are not considering as limiting. It is apparent that many modifications and variations of the present invention may be made without departing from the spirit and scope thereof. EXAMPLE 1: Synthesis of the compound represented by the following formula; EMI7.1 Into a solution of 2.72 g of 7-aminocephalosporanic acid and 1.68 g of sodium hydrogen carbonate in a mixed solvent of 30 ml of water and 20 ml of acetone, a solution of 2.13 g of l-adamantaneacetyl chloride in 5 ml of acetone was added drop by drop while stirring into the mixed solvent at OOC. After stirring the reaction mixture for one hour at OOC and further stirring for one hour at room temperature, it was left for a night at room temperature, and then the pH of the reaction mixture was adjusted to 4 by lN-hydrochloric acid to educe the thus formed crystals. The crystal was extracted with 200 ml of ethyl acetate, and after washing the extract two times with water and drying on anhydrous magnesium sulfate, the solvent was distilled off from the dried extract. Recrystallizing the residue from a mixed solvent of ethyl acetate and n-hexane, 2.77 g of white powder, 7-(adamantane-1-acetamido)cephalosporanic acid, was obtained with a yield of 62%. The characteristics of the present compound thus obtained were as follows: (1) melting point; 201 - 2040C, (2) elementary analysis; C(%) H(8) N(%) theoretical: 59.19 6.28 6.28 experimental: 59.11 6.29 6.18 (3) infrared absorption bands (RBr method); shown in Figure 1. EXAMPLE 2: Synthesis of the compound represented by the following formula; EMI8.1 A solution of 3.88 g of 7-(adamantane-l-acetamido)ce- phalosporanic acid in a mixed solvent of 50 ml of aqueous 2N-hydrochloric acid solution and 50 ml of dioxane was stirred for 16 hours at room temperature. The thus formed crystals were collected by filtration, washed two times with water. Recrystallizing the residue from a mixture of acetonitrile and dimethylformamide (5:1 by volume), 1.18 g of acicular crystals, 7- (adamantane-l-acetamido) cephalosporanolactone, were obtained with a yield of 61%. The characteristics of the present compound thus obtained were as follows: (I) melting point; 214 - 2150C, (2) elementary analysis; C(%) H(%) N(%) theoretical: 61.86 6.19 7.22 experimental: 61.73 6.15 7.21 (3) infrared absorption bands (KBr method); shown in Figure 2. EXAMPLE 3: Synthesis of the compound represented by the following formula; EMI9.1 2.24 g of 7-(adamantane-1-acetamido)cephalosporanic acid, 0.83 g of methyl 4-aminophenylacetate and 1.05 g of N,N'dicyclohexylcarbodiimide were dissolved into 30 ml of tetrahydrofuran. The thus-prepared solution was stirred at 250C for 24 hours. The crystals formed in the reaction mixture were filtered out and washed with 30 ml of tetrahydrofuran. Recrystallizing tt residue from ethanol, 1.2 g of white powdery crystals, N- (4- hydroxyphenyl) -7- (adamantane-l-acetamido) cephalosporanoamide, were obtained with a yield of 40%. The characteristics of the present compound thus obtained were as follows: (1) melting point; 190 - 1920C, (2) elementary analysis; CC%) H(%) N(8) theoretical: 62.52 6.22 7.06 experimental: 62.5 6.2 7.1 (3) infrared absorption bands (KBr method); (cm-1): 2930, 1785, 1740, 1663, 1540, 1230 refer to Figure 3 (4) ultraviolet absorption bands in acetonitrile; Xmax (nm): 223, 269 EXAMPLE 4: Synthesis of the compound represented by the following formula; EMI10.1 4.48 g of 77-(adamantane-1-acetamido)cephalosporanic acid, 1.09 g of 4-aminophenol and 2.10 g of N,N'-dicyclohexylcarbodiimide were dissolved into 60 ml of tetrahydrofuran. The thus-prepared solution was stirred at 150C for 24 hours. The crystals formed in the reaction mixture were filtered out and washed with 30 ml of tetrahydrofuran. Recrystallizing the residue from ethanol, 2.1 g of white powdery crystals, N-(4-hydroxyphenyl)- 7- (adamantane-l-acetamido) cephalosporanoamide, were obtained with a yield of 39%. The characteristics of the present compound thus obtained were as follows: (1) melting point; 190 - 1910C, (2) elementary analysis; C(%) H(%) N(%) theoretical: 62.52 6.22 7.06 experimental: 62.5 6.2 7.1 (3) infrared absorption bands (KBr method); #max (cm-1): 2930, 1788, 1747, 1663, 1521, 1227 refer to Figure 4 (4) ultraviolet absorption bands in acetonitrile; Xmax (cm) : 237, 272 EXAMPLE 5: Synthesis of the compound represented by the following formula; EMI11.1 4.48 g of 7-(adamantane-1-acetamido)cephalosporanic acid, 1.37 g of quillamine and 2.10 g of N,N'-dicyclohexylcarbodiimide were dissolved into 70 ml of tetrahydrofuran. The thusprepared solution was stirred at 100C for 34 hours. The crystals formed in the reaction mixture were filtered out and washed with 30 ml of tetrahydrofuran. Recrystallizing the residue from a mixed solvent of dimethylformamide and ethyl acetate, 2.9 g of pale-yellow powdery crystals, N-[beta-(4-4-hydroxyphenyl)ethyl]-7 (adamantane-1-acetamido)cephalosporanoamide, were obtained with a yield of 51%. The characteristics of the present compound thus obtained were as follows: (1) melting point; 154 - 156 C (decomposition), (2) elementary analysis; C(%) (%) N(%) theoretical. 63.49 6.53 7.41 experimental: 63.6 6.5 7.4 (3) infrared absorption bands (KBr method); max (cm-1): 2930, 1766, 1735, 1646, 1520, 1240 refer to Figure 5 (4) ultraviolet absorption bands in acetonitrile; #max (nm): 223, 265 EXAMPLE 6: Synthesis of the compound represented by the following formula; EMI12.1 Into a solution of 2.72 g of 7-aminocephalosporanic acid and 1.68 g of sodium hydrogen carbonate in a mixed solvent consisting of 30 ml of water and 20 ml of acetone, 5 ml of a solution of 2.0 g of adamantane-l-carboxylic acid chloride in acetone was added dropwise while stirring the solution at 0 C. After stirring the reaction mixture for 1 hour at OOC and for 1 hour at room temperature, it was left for a night at room temperature. Then, after adjusting the reaction mixture to pH of 4 by IN-hydrochloric acid, the thus educed crystals were extracted with 200 ml of ethyl acetate. The extract was washed two times with water, dried on anhydrous sodium sulfate, and the solvent was distilled off from the extract. Recrystallizing the residue from a mixed solvent of ethyl acetate and n-hexane, 2.51 g of white powder, 7-(adamantane-lamido)cephalosporanic acid, was obtained with a yield of 58z. The characteristics of the present compound thus obtained were as follows: (1) melting point; 195 - 1970C, (2) elementary analysist C(%) H(%) N(z) theoretical: 58.06 5.99 6.45 experimental: 58.05 5.87 6.41 (3) infrared absorption bands (KBr method); shown in Figure 6. EXAMPLE 7: Synthesis of the compound represented by the following formula; EMI14.1 Into a mixed solvent consisting of 50 ml of aqueous 2N-hydrochloric acid solution and 50 ml of dioxane, 3.74 g of 7- (adamantane-l-amido) cephalosporanic acid was dissolved, and the solution was stirred for 16 hours at room temperature. The thus formed crystals were collected by filtration of the reaction mixture, washed two times with water. Recrystallizing from a mixture of acetonitrile and dimethylformamide (5:1 by volume), 1.21 g of acicular crystals, 7-(adamantane-l-amido)cephalosporanolactone, were obtained with a yield of 65%. The characteristics of the present compound thus obtained were as follows: (1) melting point; 240 - 2420C, (2) elementary analysis; C(%) HC%) N(%) theoretical: 60.96 5.88 7.49 experimental: 60.90 5.81 7.48 (3) infrared absorption bands (KBr method); Shown in Figure 7. TOXICOLOGICAL AND PHARMACOLOGICAL ACTIVITIES OF THE PRESENT COMPOUNDS: EXAMPLE 8: Acute toxicity of the present compounds were determined as follows. Each of the present compounds was dispersed in a physiological saline solution. The dispersion was administered to an ICR-JCL mouse orally by a stomach sonde or intraperitoneally by injection at a predetermined amount. After administration, the intoxication symtoms were continuously observed for a week and both survival and dead mice were autopsied to observe. LD50 value was obtained from the cumulative mortality of the treated mice by applying the data to the Litchfield-Wilcoxon's graphical method. All of the present compounds gave LD50 value of more than 10 g/kg in both oral and intraperitoneal administrations. The LD50 value of cephalotin sodium as a comparative antibiotic is about 5 g/kg. These results show that the present compound is a safe substance having a low toxicity. EXAMPLE 9: Effect of the present compounds on the intestinal bacterial colonies was examined. Each of the present compounds was orally administered to mice (one group consisting of five female ICR mice of 6-week-old) for two consecutive days at a dose of 500 mg/kg/day. Before and on the first day after the administration, feces of each mouse were collected and diluted with an anaerobic diluent (phosphoric buffer solution) of 100 times volume and ground. 0.1 ml of the diluted and ground feces was smeared on each culture medium shown in Table 1 and cultured aerobically or anaerobically (according to the anaerobic glove box method) under each condition shown in Table 1. The number of each bacterium shown in Table 1 was counted. The results are shown in Table 2. As seen from Table 2, the number of Escherichia coli showed no remarkable change as compared to that before administration in the case of each of the present compounds, while that number increased in the case of cephalotin as a comparative antibiotic. Further, the number of Lactobacillus acidophilus decreased in the case of cephalotin while such a decrease was not observed in the case of the present compounds. These results show that the present compounds do not affect the intestinal bacterial colonies in living bodies. Table 1: Culture medium and culture condition of bacteria EMI17.1 <tb> Bacterium <SEP> Culture <SEP> Culture <SEP> condition <tb> <SEP> medium <tb> Escherinchia <SEP> coli <SEP> DHL <SEP> agar <SEP> aerobic, <SEP> 37 C, <SEP> one <SEP> day <tb> Pseudomonas <SEP> aeruginosa <SEP> NAC <SEP> agar <SEP> aerobic, <SEP> 37 C, <SEP> one <SEP> day <tb> Streptococcus <SEP> spp. <SEP> TATAC <SEP> agar <SEP> aerobic, <SEP> 37 C, <SEP> one <SEP> day <tb> Lactobacillus <SEP> acidophilus <SEP> LBS <SEP> agar <SEP> anaerobic, <SEP> 37 C, <SEP> five <SEP> days <tb> Lactobacillus <SEP> bifidus <SEP> BS <SEP> agar <SEP> anaerobic, <SEP> 37 C, <SEP> five <SEP> days <tb> Bacteroides <SEP> NBGT <SEP> agar <SEP> anaerobic, <SEP> 37 C, <SEP> five <SEP> days <tb> Table 2 EMI18.1 Example <SEP> Logarithmic <SEP> value <SEP> of <SEP> the <SEP> number <SEP> of <SEP> bacterial <SEP> cells <SEP> per <SEP> one <SEP> gram <SEP> of <SEP> feces <tb> <SEP> No. <SEP> E. <SEP> coli <SEP> Ps. <SEP> aeruginosa <SEP> Strept. <SEP> spp. <SEP> L. <SEP> acidophilus <SEP> L. <SEP> bifidus <SEP> Bacteroides <tb> <SEP> 1 <SEP> 6.4 <SEP> < 3.0 <SEP> 6.5 <SEP> 8.9 <SEP> 8.3 <SEP> 8.3 <tb> <SEP> 2 <SEP> 6.5 <SEP> < 3.0 <SEP> 6.8 <SEP> 9.1 <SEP> 8.4 <SEP> 8.2 <tb> <SEP> 3 <SEP> 6.6 <SEP> < 3.0 <SEP> 6.8 <SEP> 9.0 <SEP> 8.3 <SEP> 8.6 <tb> <SEP> 4 <SEP> 6.5 <SEP> < 3.0 <SEP> 6.7 <SEP> 8.9 <SEP> 8.6 <SEP> 8.7 <tb> <SEP> 5 <SEP> 6.4 <SEP> < 3.0 <SEP> 6.8 <SEP> 8.9 <SEP> 8.5 <SEP> 8.7 <tb> <SEP> 6 <SEP> 6.4 <SEP> < 3.0 <SEP> 6.5 <SEP> 8.8 <SEP> 8.8 <SEP> 8.2 <tb> before <SEP> administra- <SEP> 6.4 <SEP> < 3.0 <SEP> 6.8 <SEP> 9.0 <SEP> 8.4 <SEP> 8.3 <tb> tion <tb> Cepha- <SEP> 9.9 <SEP> < 3.0 <SEP> 9.0 <SEP> 4.1 <SEP> 9.2 <SEP> 7.2 <tb> lotin <tb> EXAMPLE 10: Antibacterial antivity of the present compounds was examined as follows. Antibacterial activity of each of the present compounds was examined against the following two bacteria according to the standard method of Japan Society of Chemotherapy: Escherichia coli IFO 12734 and Staphylococcus aureus 1AM 1011 Each bacterial strain was inoculated into the Mueller Hinton's culture medium and cultured at 370C for 18 to 48 hours. The culture medium was diluted so as to contain 1 x 10 cells of the bacteria per one ml, and the obtained medium was used as the bacterial specimen. Agar plates were prepared by adding one part by weight of each solution of the present compounds having a predetermined concentration to nine parts by weight of Mueller-Hinton's culture medium. A loopful amount of the bacterial specimen prepared above was smeared to make a streak of about 2 cm on each agar plate and cultured at 370C for 18 to 24 hours. The minimum concentration for completely inhibiting proliferation of the bacteria (referred to as MIC) was determined. The results are shown in Table 3. Table 3 EMI20.1 <tb> <SEP> MIC <tb> Example <tb> <SEP> No. <tb> <SEP> E. <SEP> coli <SEP> Stash. <SEP> aureus <tb> 1 <SEP> 50 <SEP> 0.78 <tb> 2 <SEP> 100# <SEP> <SEP> 3.13 <tb> <SEP> 3 <SEP> 100# <SEP> <SEP> 100# <tb> <SEP> 4 <SEP> 4 <SEP> 100 < <SEP> 100 < <tb> <SEP> 5 <SEP> 100 < <SEP> 1.56 <tb> <SEP> 6 <SEP> - <SEP> 25 <SEP> 0.39 <tb> EXAMPLE 11: The following experiment was carried out in order to prove that the present compound is activated in a living body. As an enzyme for activating metabolism, a rat liver homogenate (S-9, manufactured by Oriental Yeast Company, Japan) was used in the following composition per one ml (hereinafter referred to as S-9 mix). S-9 0.5 ml KCl 3.3 mol MgCl2#6H2O 8 mol Glucose-6-phosphate 5 mol NaDH 4 mol NADPA 4 umol 0.2M phosphoric buffer solution (pH 7.4) 0.5 ml 0.1 ml of each solution of the present compounds at a concentration of various value was mixed with 0.9 ml of S-9 mix or 0.9 ml of 0.1 M phosphoric buffer solution (as a control) and the obtained mixture was incubated at 370C for 20 min with shaking. Staphylococcus aureus IAM 1011 was inoculated into a Mueller-Hinton's culture medium and cultured at 370C for 18 hours. The culture medium was adjusted to a cell concentration of 1 x 10 per one ml and mixed with 50 times by volume of Mueller-Hinton's agar culture medium to obtain an agar plate. A penicillin cup of 8 mm in diameter was placed on the agar plate prepared above, and into the cup 0.1 ml of the mixture was introduced and allowed to stand at 40C for 2 hours and then cultured at 370C for 18 hours to measure the diameter of a circle in which the proliferation of bacteria was inhibited (proliferation-inhibiting circle). The results are shown in Table 4. In Table 4, the proliferation-inhibiting index is shown with the ratio (%) of the diameter of the proliferation-inhibiting circle obtained by using each of the present compounds to that obtained by using the comparative compound. Index 0 + 0-1 + 1-33 ++ 33-66 66-100 Table 4 EMI22.1 <tb> <SEP> Proliferation-inhibiting <SEP> index <SEP> (%) <tb> Example <SEP> No. <tb> <SEP> Before <SEP> adding <SEP> 5-9 <SEP> mix <SEP> After <SEP> adding <SEP> S-9 <SEP> mix <tb> <SEP> 3 <SEP> + <SEP> <tb> <SEP> 4 <SEP> - <SEP> + <tb> <SEP> 5 <SEP> + <tb> <SEP> 6 <SEP> + <tb> As seen from Table 4, the antibacterial activity of the present compound is activated by an enzyme in a living body, although it itself shows a low antibacterial activity in the absence of an activating enzyme. EXAMPLE 12: Effect of the present compounds on the infection was examined. Escherichia coli IFO 12734 (1.4 x 108) was inoculated intraperitoneally to ddY-SPF mice (a group consisting of 20 mice). Just after and at 4 hours after the infection, each of the present compounds was administered orally at a dose of 500 mg/kg and the mortality of the mice due to the infection was observed for 7 days. More than 35% of the mice administered with the present compound survived even on the 7th day after the infection, while all mice without the administration with the present compound died on the 2nd day after infection. The results show that the present compound is an effective medicine for oral administration against an infectious disease. MANUFACTURE OF THE PHARMACEUTICAL PREPARATIONS: EXAMPLE 13: (1) Tablet A tablet was prepared by a following composition in one tablet of 200 mg; the present compound of Example 3 175 mg lactose 16 mg starch 5 mg hydroxypropylcellulose 3 mg magnesium stearate 1 mg The present compound and lactose were mixed and then an aqueous solution of hydroxypropylcellulose was admixed, and the mixture was kneaded, dried and pulverized. Then magnesium stearate dispersed previously into starch was admixed and the mixture was made into a tablet by the conventional method for tabletting. (2) Granule A granule was prepared by a following composition; the present invention of Example 4 176 mg lactose 16 mg starch 4 mg hydroxypropylcellulose 4 mg The present compound, starch and lactose were mixed, and an aqueous solution of hydroxypropylcellulose was admixed and the mixture was dried and pulverized. The pulverized material was sifted by 12 to 48 mesh sieves to obtain a granule.

Claims: CLAIMS 1. A cephalosporin derivative having the general formula(I): EMI25.1 wherein R1 is EMI25.2 R2 is -OR3 wherein R3 is a hydrogen atom, an alkyl group having 1 to 4 carbon atoms or a pharmaceutically acceptable cation, EMI25.3 wherein n is O, 1 or 2, EMI25.4 wherein R3 is as defined above.' or -COR2 together with -CH2OCOCH3 form a lactone ring. 2. A derivative according to claim 1, which is 7- (adamantane-1-acetamido ) cephalosporanic acid or 7-(adam antane-l-acetamido)cephalosporanolactone. 3. A derivative according to claim 1, which is N-(4-carbomethoxymethylphenyl)-7-(adamantane-1-acetamido)cephalosporanoamide. 4. A derivative according to claim 1, which is N-(4-hydroxyphenyl)-7-(adamantane-1-acetamido)cephalosporanoamide. 5. A derivative according to claim 1, which is N-[beta-(4-hydroxyphenyl)ethyl]-7-(adamantane-1-acetamido)cephalosporanoamide. 6. A derivative according to claim 1, which is 7- (adamantane-1-amido ) cephalosporanic acid or 7-(adamantanel-amido)cephalosporanolactone. 7. A process for the preparation of a cephalosporin derivative as claimed in claim 1, which process comprises reacting 7-aminocephalosporanic acid having the general formula (II): EMI26.1 wherein R3 is as defined in claim 1, with an acid chloride of formula (III): EMI26.2 to form a cephalosporin derivative as claimed in claim 1 wherein R2 is -OR3; if desired reacting the cephalosporin derivative wherein R2 is -OR3 with an amine of the general formula (IV): NH2-R4 (IV) wherein R4 EMI26.3 wherein n and R3 are as defined in claim 1, to form a cephalosporin derivative as claimed in claim 1 wherein R2 is the same as R4 above; and if desired converting the cephalosporin derivative wherein R2 is the same as R4 above to a cephalosporin derivative as claimed in claim 1 wherein -COR2 and -CH2OCOCH3 together form a lactone ring. 8. A pharmaceutical composition comprising, as active ingredient, a cephalosporin derivative as claimed in any one of claims I to 6 or which has been prepared by a process as claimed in claim 7, together with a pharmaceutically acceptable carrier t diluent or adjuvant. 9. A pharmaceutical composition according to claim 8 in a unit dosage form.

Inventors: ANDO, TAKAO, FUJII, MASAHIKO, FURUSHO, TAKAO, KANNO, AKIHIKO, MUTO, SHIGEAKI, NIIMURA, KOUICHI, YOSHIKUMI, CHIKAO
Applicants: KUREHA KAGAKU KOGYO KABUSHIKI KAISHA
Application year: 1982
Main classification: C07D501
IPC codes: C07D513, C07D501, A61K31